Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. 1988

R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, Sydney, Australia.

1. 1-methyl xanthine (1-MX) is metabolized exclusively to 1-methyl uric acid (1-MU) by the enzyme xanthine oxidase. 2. The ratio of 1-MU to 1-MX in the urine, following a dose of 50 mg of 1-MX infused intravenously over 20 min, was used to measure the inhibition of xanthine oxidase induced by different doses of allopurinol. 3. Normal volunteers (n = 8) were given allopurinol 50, 100, 300 and 600 mg daily for 1 week each, in random order and 1 week separated each treatment. Inhibition of xanthine oxidase was assessed twice, on the last 2 days of each treatment week. 4. Steady-state oxipurinol concentrations increased linearly with increasing dose of allopurinol. 5. There was a hyperbolic relationship between the 1-MU/1-MX ratio and plasma oxipurinol concentrations, with an initial steep decline in the ratio which plateaued when plasma oxipurinol was around 4-6 mg l-1. This reduction in the ratio was quickly reversible upon cessation of allopurinol. 6. The 50% and 90% effective inhibitory oxipurinol concentrations, in relation to the 1-MU-/1-MX ratio were 1.4 +/- 0.46 and 4.08 +/- 2.03 mg l-1 respectively. 7. The concentration of oxipurinol required for almost complete inhibition of the enzyme was substantially less than those often observed in clinical practice.

UI MeSH Term Description Entries
D008297 Male Males
D010117 Oxypurinol A xanthine oxidase inhibitor. Alloxanthine,Oxipurinol
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000493 Allopurinol A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. Allohexal,Allohexan,Alloprin,Allopurin,Allorin,Allpargin,Allural,Apulonga,Apurin,Atisuril,Bleminol,Caplenal,Capurate,Cellidrin,Embarin,Foligan,Hamarin,Jenapurinol,Lopurin,Lysuron,Milurit,Milurite,Novopurol,Pan Quimica,Progout,Pureduct,Purinol,Remid,Rimapurinol,Roucol,Suspendol,Tipuric,Uribenz,Uridocid,Uripurinol,Urosin,Urtias,Xanthomax,Xanturic,Zygout,Zyloprim,Zyloric
D014969 Xanthine Oxidase An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria. Hypoxanthine Oxidase,Hypoxanthine Dehydrogenase,Hypoxanthine-Xanthine Oxidase,Purine-Xanthine Oxidase,Dehydrogenase, Hypoxanthine,Hypoxanthine Xanthine Oxidase,Oxidase, Hypoxanthine,Oxidase, Hypoxanthine-Xanthine,Oxidase, Purine-Xanthine,Oxidase, Xanthine,Purine Xanthine Oxidase

Related Publications

R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
December 1987, British journal of rheumatology,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
October 1968, Clinical science,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
January 1966, Texas medicine,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
November 1980, Clinical chemistry,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
December 2009, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
June 2016, Molecules (Basel, Switzerland),
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
December 1983, Annals of the rheumatic diseases,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
March 1977, Journal of chromatography,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
September 1983, Die Medizinische Welt,
R O Day, and J Miners, and D J Birkett, and G G Graham, and A Whitehead
June 2008, Nucleosides, nucleotides & nucleic acids,
Copied contents to your clipboard!